

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 64

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 64

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 64

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum zibrofusidicum

zibrofusidic acid


(17Z)-16β-(acetyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dien-21-oic acid

acide zibrofusidique

acide (17Z)-16β-(acétyloxy)-24-bromo-3α,11α-dihydroxy-29-norprotosta-17(20),24-dién-21-oïque

ácido zibrofusídico

ácido (17Z)-16β-(acetiloxi)-24-bromo-3α,11α-dihidroxi-29-norprotosta-17(20),24-dien-21-oico

C₃₁H₄₇BrO₆**afatinibum**

afatinib


(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxy]quinoxazolin-6-yl]-4-(dimethylamino)but-2-enamide



afatinib

(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxy]quinoxazolin-6-yl]-4-(diméthylamino)but-2-énamide

afatinib

(2E)-N-[4-(3-cloro-4-fluoroanilino)-7-[(3S)-oxolan-3-il]oxi]quinoxazolin-6-il]-4-(dimetilamino)but-2-enamida

C₂₄H₂₅ClFN₅O₃

atagabalinum atagabalin	[(3 <i>S</i> ,4 <i>S</i>)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique acid
atagabaline	acide [(3 <i>S</i> ,4 <i>S</i>)-1-(aminométhyl)-3,4-diméthylcyclopent-1-yl]acétique
atagabalina	ácido [(3 <i>S</i> ,4 <i>S</i>)-1-(aminometil)-3,4-dimetiliclopent-1-il]acético
	C ₁₀ H ₁₉ NO ₂
	
barasertibum barasertib	2-{éthyl[3-({4-[(5-{2-[(3-fluorophényl)amino]-2-oxoéthyl})-1 <i>H</i> -pyrazol-3-yl]amino}quinazolin-7-yl)oxy)propyl]amino}éthyl dihydrogen phosphate
barasertib	dihydrogénophosphate de 2-{éthyl[3-({4-[(5-{2-[(3-fluorophényl)amino]-2-oxoéthyl})-1 <i>H</i> -pyrazol-3-yl]amino}quinazolin-7-yl)oxy)propyl]amino}éthyle
barasertib	dihidrógenofosfato de 2-{etil[3-({4-[(5-{2-[(3-fluorofenil)amino]-2-oxoetil})-1 <i>H</i> -pirazol-3-il]amino}quinazolin-7-il)oxi)propil]amino}etilo
	C ₂₆ H ₃₁ F N ₇ O ₆ P
	
benralizumabum # benralizumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> IL5RA (interleukin 5 receptor subunit alpha, CD125)], humanized monoclonal antibody; gamma1 heavy chain (1-451) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) - <i>Homo sapiens</i> IGHG1*01 (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; (230-230":233-233")-bisdisulfide dimer
benralizumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IL5RA (sous-unité alpha du récepteur de l'interleukine 5, CD125)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-451) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) - <i>Homo sapiens</i> IGHG1*01 (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

benralizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ILR5A (subunidad alfa del receptor de la interleukina 5, CD125)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-451) [VH humanizada (*Homo sapiens* IGHV1-46*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SYVIHWVRQR PGQGLAWMGY 50
INPYNQGTKY NERFKGKVTI TSDRSTSTVY MELSSLRSED TAVYLCGREG 100
IRYYGLLDY WQQTGLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSV VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMIKRTV PEVTCVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFCSS VMHEALHNHY TQKSLSLSPG 450
K 451

Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVIGDRVT ITCGTSEDII NYLNWYQQKPK GKAPKLLIYH 50
TSRLQSGVPS RFGSGSGTD FTLTISLQEP EDFATYYCQQ GYTLPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L 23'-88' 134'-194'
23"'-88"' 134"'-194"
Inter-H-L 224-214' 224"-214"
Inter-H-H 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301, 301"

cabiortaxetanum

cabiortaxetan

2,2',2"-[10-(2-[[6-({5-[(3aS,4S,6aR)-2-oxohexahidro-1H-tieno[3,4-d]imidazol-4-yl]pentil)amino]hexil)amino]-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triil]triacetic acid


cabiortaxétan

acide 2,2',2"-[10-(2-[[6-({5-[(3aS,4S,6aR)-2-oxohexahidro-1H--thiéno[3,4-d]imidazol-4-yl]pentil)amino]hexil)amino]-2-oxoéthyl)-1,4,7,10-tétraazacyclododécane-1,4,7-triil]triacétique

cabiortaxetán

ácido [10-(2-[[6-({5-[(3aS,4S,6aR)-2-oxohexahidro-1H-tieno[3,4-d]imidazol-4-il]pentil)amino]hexil)amino]-2-oxoetil)-1,4,7,10-tetraazaciclododecano-1,4,7-triilo]triacético

C₃₂H₅₈N₈O₈S




canagliflozinum
canagliflozin(1*S*)-1,5-anhydro-1-*C*-(3-([5-(4-fluorophenyl)thiophen-2-yl]methyl)-4-methylphenyl)-*D*-glucitol

canagliflozine

(1*S*)-1,5-anhydro-1-*C*-(3-([5-(4-fluorophényl)thiophén-2-yl]méthyl)-4-méthylphényl)-*D*-glucitol


canagliflozina

(1*S*)-1,5-anhydro-1-*C*-(3-([5-(4-fluorofenil)tiopen-2-il]metil)-4-metilfenil)-*D*-glucitol $C_{24}H_{25}FO_5S$ **carotegrastum**
carotegrast(2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phenyl}propanoic acid

carotégrast

acide (2*S*)-2-(2,6-dichlorobenzamido)-3-{4-[6-(diméthylamino)-1-méthyl-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phényl}propanoïque

carotegrast

ácido (2*S*)-2-(2,6-diclorobenzamido)-3-{4-[6-(dimetilamino)-1-metil-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]fenil}propanoico $C_{27}H_{24}Cl_2N_4O_5$ 

condoliasum #	
condoliase	endolyase, chondroïtine ABC (C-ABC). glycosaminoglycan lyase chondroïtine ABC endolyase 1 (chondroïtinase ABC) <i>Proteus vulgaris</i>
condoliase	endolyase, chondroïtine ABC (C-ABC). glycosaminoglycane lyase chondroïtine ABC endolyase 1 (chondroïtinase ABC) <i>Proteus vulgaris</i>
condoliasa	endoliasa, condroitina ABC (C-ABC). glicosaminoglicano liasa condroitina ABC endoliasa 1 (condroitinasa ABC) <i>Proteus vulgaris</i>

C₅₀₃₉H₇₇₇₀N₁₃₆₀O₁₅₂₅S₂₂

ATSNPAFDPK	NLMQSEIYHF	AQNNPLADFS	SDKNSILTLS	DKRSIMGQNS	50
LLWKWKGSS	FTLHKKLIVP	TDKEASKAWG	RSSTPVFSFW	LYNEKPIDGY	100
LTIDFGEKLI	STSEAQAGFK	VKLDFTGWRA	VGVSLNNDLE	NREMTLNATN	150
TSSDGTQDSI	GRSLGAKVDS	IRFKAPSNVS	QGEIYIDRIM	FVSDDARYQW	200
SDYQVKTRLS	EPEIQFHNVK	PQLPVTPENL	AAIDLIRQRL	INEFVGGEKE	250
TNLALEENIS	KLKSDFDALN	IHTLANGGTQ	GRHLITDKQI	IYQPENLNS	300
QDKQLFDNYV	ILGNYTTLMF	NISRAYVLEK	DPTQKAQLKQ	MYLLMTKHLL	350
DQGFWKGSAL	VTTHHWGYSS	RWYIISTLLM	SDALKEANLQ	TQVYDSSLWY	400
SREFKSSPDM	KVSADSSDL	YFNTLSRQHL	ALLLEPDDQ	KRINLVNTFS	450
HYITGALTQV	PPGGKDGRLP	DGTAWRHEGN	YPGYSFPAPK	NASQLYLLLR	500
DTPFSVGESE	WNNLKKAMVS	AWIYSNPEVG	LPLAGRHPFN	SPSLKSVAAQ	550
YYWLAMSAKS	SPDKTLASIY	LAI SDKTQNE	STAI FGETIT	PASLPQGFYA	600
FNGGAFGIHR	WQDKMVTLKA	YNTNWSSEI	YNKDNRYGRY	QSHGVAQIVS	650
NGSQLSQGYQ	QEGWDWNRME	GATTIHLPLK	DLDSPKPHTL	MQRGERGFSG	700
TSSLEGQYGM	MAFNLIYPAN	LERFDPNFTA	KKSVLAADNH	LIFIGSNINS	750
SDKNKNVETT	LFQHAITPTL	NTLWINGQKI	ENMPYQTTLQ	QGDWLDISNG	800
NGYLITQAEK	VNVSROHQVS	AENKNRQFTE	GNFSSANIDH	STRPKDASYE	850
YMFVLDATPE	KMGEMAQKFR	ENNGLYQVLR	KDKDVHILLD	KLSNVTGYAF	900
YQPASIEDKW	IKKVNKPAIV	MTHRQKDTLI	VSAVTPDLNM	TRQKAATPVT	950
INVTINGKWQ	SADKNSEVKY	QVSGDNTELT	FTSYFGIPQE	IKLSPLP	997

dalotuzumabum #	
dalotuzumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (<i>Homo sapiens</i> IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (118-447)], (220-219)-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer
dalotuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (<i>Homo sapiens</i> IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (118-447)], (220-219)-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure
dalotuzumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> IGF1R (receptor del factor de crecimiento similar a la insulina 1(IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizada (<i>Homo sapiens</i> IGHV4-61*08 (79.80%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (118-447)], (220-219)-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (<i>Homo sapiens</i> IGKV2-29*02 (78.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQQSGPG LVKPSQTLST TCTVSGWSIS GGWLWNWIRQ PPGKGLQWIG 50
 WISWDGTTNNW KPSLKDRTVI SVDTSKNQFS LKLSSTVTAAD TAVWWCARWG 100
 RVFFDWWGQG TLVTVSSAST KGPSVFFLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
 NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIISKAK GQPREPQVYT 350
 LPPSRREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LLSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
 DIVMTQSPLS LPVTPGQPAS ISCRSSQSIV HSNNGTTLQW WLQKPGQSPQ 50
 LLIWKVSNRL WGVVDFRFSGS GSGTDFTLKI SRVQAQDVGV WWCFCQSHVP 100
 WTFGQGTQVQ IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
 VQWKVDNALQ SGNMQESVTE QDSKSTYSL SSSLTTLTKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"

Intra-L 23"-93" 139"-199"
 23"-93" 139"-199"

Inter-H-L 220-219" 220"-219"

Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 297, 297"

danoprevirum

danoprevir

(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*tert*-butoxycarbonyl)amino]-14*a*-[*N*-(cyclopropanesulfonyl)carbamoil]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-2-yl 4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate


danoprévir

4-fluoro-1,3-dihydro-2*H*-isoindole-2-carboxylate de (2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*tert*-butoxycarbonyl)amino]-14*a*-[*N*-(cyclopropanesulfonyl)carbamoil]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadécahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadécin-2-yle

danoprevir

4-fluoro-1,3-dihydro-2*H*-isoindol-2-carboxilato de (2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-6-[(*tert*-butoxicarbonil)amino]-14*a*-[*N*-(ciclopropanosulfonil)carbamoil]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahidrociclopropa[e]pirrolo[1,2-*a*][1,4]diazacyclopentadecin-2-ilo

C₃₅H₄₆FN₅O₉S



derenofyllinum


derenofylline

trans-4-[(2-phenyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

dérénofylline

trans-4-[(2-phényl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexanol

derenofilina

trans-4-[(2-fenil-7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]ciclohexanolC₁₈H₂₀N₄O**dilmapimodum**


dilmapimod

8-(2,6-difluorophenyl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-methylphenyl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod

8-(2,6-difluorophényl)-2-[(1,3-dihydroxypropan-2-yl)amino]-4-(4-fluoro-2-méthylphényl)pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

dilmapimod

8-(2,6-difluorofenil)-2-[(1,3-dihidroxiopropan-2-il)amino]-4-(4-fluoro-2-metilfenil)pirido[2,3-*d*]pirimidin-7(8*H*)-onaC₂₃H₁₉F₃N₄O₃**dinaciclibum**

dinaciclib



3-[[[3-ethyl-5-[(2*S*)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl]amino)methyl]pyridine 1-oxide

dinaciclib

1-oxide de 3-[[[3-éthyl-5-[(2*S*)-2-(2-hydroxyéthyl)pipéridin-1-yl]pyrazolo[1,5-*a*]pyrimidin-7-yl]amino)méthyl]pyridine

dinaciclib

1-óxido de 3-[[[3-etil-5-[(2*S*)-2-(2-hidroxietil)piperidin-1-il]pirazolo[1,5-*a*]pirimidin-7-il]amino)metil]piridina

**dipraglurantum**

dipraglurant



6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyridine

dipraglurant

6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2-a]pyridine

dipraglurant

6-fluoro-2-[4-(piridin-2-il)but-3-in-1-il]imidazo[1,2-a]piridina

**duvoglustatum**



duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hydroxymethyl)piperidine-3,4,5-triol

duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

duvoglustat

(2*R*,3*R*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol**efatutazonum**

efatutazone



rac-5-[(4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1*H*-benzimidazol-2-yl]methoxy]phenyl)methyl]-1,3-thiazolidine-2,4-dione

éfatutazone

rac-5-[(4-[[6-(4-amino-3,5-diméthylphénoxy)-1-méthyl-1*H*-benzimidazol-2-yl]méthoxy]phényl)méthyl]thiazolidine-2,4-dione

efatutazona

rac-5-[(4-[[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1*H*-benzoimidazol-2-il]metoxi]fenil)metil]-1,3-tiazolidina-2,4-diona

and enantiomer
et énantiomère
y enantiomero**emicerfontum**
emicerfont





1-{1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

emicerfont

1-{1-[1-(4-méthoxy-2-méthylphényl)-6-méthyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

emicerfont

1-{1-[1-(4-metoxi-2-metilfenil)-6-metil-2,3-dihidro-1H-pirrolo[2,3-b]piridin-4-il]-1H-pirazol-3-il}imidazolidin-2-ona

**florbetabenum** (¹⁸F)
florbetaben (¹⁸F)4-((1E)-2-(4-(2-[2-(2-[¹⁸F]fluoroethoxy)ethoxy]ethoxy)phenyl)eth-1-en-1-yl)-N-methylanilineflorbétabène (¹⁸F)4-((1E)-2-(4-(2-[2-(2-[¹⁸F]fluoroéthoxy)éthoxy]éthoxy)phényl)éth-1-én-1-yl)-N-méthylanilineflorbetabén (¹⁸F)4-((1E)-2-(4-(2-[2-(2-[¹⁸F]fluoroetoxi)etoxi]etoxi)fenil)et-1-en-1-il)-N-metilanilina

foretinibum

foretinib


N-[3-fluoro-4-({6-methoxy-7-[3-(morpholin-4-yl)propoxy]quinolin-4-yl}oxy)phenyl]-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

forétinib

N-[3-fluoro-4-({6-méthoxy-7-[3-(morpholin-4-yl)propoxy]quinoléin-4-yl}oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

foretinib

N-[3-fluoro-4-({6-metoxi-7-[3-(morfolin-4-il)propoxi]quinolin-4-il}oxi)fenil]-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

C₃₄H₃₄F₂N₄O₆**glebatumumabum #**

glebatumumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotein transmembrane NMB, hematopoietic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (221-221":222-222":225-225":228-228")-tetrakisdisulfide dimer

glebatumumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotéine transmembranaire NMB, facteur de croissance hématopoïétique inductible type neurokinine-1, HGFIN) domaine extracellulaire], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (221-221":222-222":225-225":228-228")-tétrakisdisulfure

glebatumumab

immunoglobulina G2-kappa, anti-[*Homo sapiens* GPNMB (glicoproteína transmembranosa NMB, factor de crecimiento hematopoyético inductible tipo neuroquinina-1, HGFIN) dominio extracelular], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01 (120-445)], (133-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (221-221":222-222":225-225":228-228")-tétrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQESGPG LVKPSQTLST TCTVSGGSIS SFNYWWSWIR HHPGKGLEWI 50
 GYIYYSGSTY SNPSLKRVT ISVDTSKNQF SLTLSSVTA A DTAVYYCARG 100
 YNWNVFDYWG QGTLVTVSSA STKGPSVFPPL APCSRSTSES TAALGCLVKD 150
 YFPEPVTVSW NSGALTSVH TFPVAVLQSSG LYSLSVTVV PSSNFGTQTY 200
 TCNVDHKPSN TKVDKTVRER CCVECPPEA PVVAGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
 VSVLTVVHQD WLNKGKEYCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLF 350
 PSREEMTKNQ VSLTCLVKG F YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
 SFFFLYKLTIV DKSRWQQGNV FSCSVMEAL HNHYTQKSL S LSPGK 445

Light chain / Chaîne légère / Cadena ligera
 EIVMTQSPAT LSVSPGERAT LSCRASQSV D NNLVWYQQK P GQAPRLLIYG 50
 ASTRATGIPA RFGSGSGSTE FTLTISLQS EDFAVYCCQ YNNWPPWTFG 100
 QGTRKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TLSKADYEK K VYACEVTHQ 200
 GLSSPVTKSF NRGEC 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-97 146-202 259-319 365-423
 22"-97" 146"-202" 259"-319" 365"-423"
 Intra-L 23"-88" 135"-195"
 23"-88" 135"-195"
 Inter-H-L 133-215' 133"-215"
 Inter-H-H 221-221" 222-222" 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 295, 295"

guaraprosolum
 guaraprolose

(1→6)-α-D-galactopyrano-(1→4)-β-D-mannopyranan
 2-hydroxypropyl ether


guaraprolose

éther 2-hydroxypropylique du (1→6)-α-D-galactopyrano-
 (1→4)-β-D-mannopyranane

guaraprolosa

éter 2-hidroxiopropílico de (1→6)-α-D-galactopirano-
 (1→4)-β-D-mannopirano

$[C_{18}H_{30}O_{15} (C_3H_6O)_x]_n$



R = H, CH₂-CHOH-CH₃

lasmiditanum
 lasmiditan



2,4,6-trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-
 2-yl}benzamide

lasmiditan

2,4,6-trifluoro-N-{6-[(1-méthylpipéridine-4-yl)carbonyl]pyridin-
 2-yl}benzamide

lasmiditán

2,4,6-trifluoro-N-{6-[(1-metilpiperidina-4-il)carbonil]piridin-
 2-il}benzamida

**latrepirdinum**


latrepirdine

2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1*H*-pyrido[4,3-*b*]indole

latrépirdine

2,8-diméthyl-5-[2-(6-méthylpyridin-3-yl)éthyl]-2,3,4,5-tétrahydro-1*H*-pyrido[4,3-*b*]indole

latrepirdina

2,8-dimetil-5-[2-(6-metilpiridin-3-il)etil]-2,3,4,5-tetrahydro-1*H*-pirido[4,3-*b*]indol**linifanibum**



linifanib

1-[4-(3-amino-1*H*-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea

linifanib

1-[4-(3-amino-1*H*-indazol-4-yl)phényl]-3-(2-fluoro-5-méthylphényl)urée

linifanib

1-[4-(3-amino-1*H*-indazol-4-il)fenil]-3-(2-fluoro-5-metilfenil)urea**lunacalcipolum**

lunacalcipol


(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-methylpropane-2-sulfonyl)-9,10-secochola-5,7,10(19),16,23-pentaene-1,3-diol

lunacalcipol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-méthylpropane-2-sulfonyl)-9,10-sécochola-5,7,10(19),16,23-pentaène-1,3-diol

lunacalcipol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-24-(2-metilpropano-2-sulfonyl)-9,10-seccola-5,7,10(19),16,23-pentaeno-1,3-diol

C₂₈H₄₂O₄S**mapracoratum**


mapracorat

(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-methyl-2-[(2-methylquinolin-5-yl)amino]methyl]pentan-2-ol

mapracorat

(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-yl)-4-méthyl-2-[(2-méthylquinoléin-5-yl)amino]méthyl]pentan-2-ol

mapracorat

(2*R*)-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydro-1-benzofuran-7-il)-4-metil-2-[(2-metilquinolin-5-il)amino]metil]pentan-2-olC₂₅H₂₆F₄N₂O₂**marizomibum**


marizomib

(1*R*,4*R*,5*S*)-4-(2-chloroethyl)-1-[(*S*)-[(1*S*)-cyclohex-2-en-1-yl](hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

marizomib

(1*R*,4*R*,5*S*)-4-(2-cloroéthyl)-1-[(*S*)-[(1*S*)-cyclohex-2-én-1-yl](hydroxy)méthyl]-5-méthyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

marizomib

(1*R*,4*R*,5*S*)-4-(2-cloroetil)-1-[(*S*)-[(1*S*)-ciclohex-2-en-1-il](hidroxi)metil]-5-metil-6-oxa-2-azabicyclo[3.2.0]heptano-3,7-dionaC₁₅H₂₀ClNO₄

mavrilimumabum # mavrilimumab	immunoglobulin G4-lambda, anti-[<i>Homo sapiens</i> CSF2RA (granulocyte-macrophage colony-stimulating factor receptor subunit alpha, GM-CSF-R-alpha, CD116)], <i>Homo sapiens</i> monoclonal antibody; gamma4 heavy chain (1-447) [<i>Homo sapiens</i> VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfide with lambda light chain (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') - IGLC2*01 (112'-217')]; (226-226":229-229")-bisdisulfide dimer
mavrilimumab	immunoglobuline G4-lambda, anti-[<i>Homo sapiens</i> CSF2RA (sous-unité alpha du récepteur du facteur stimulant les colonies de granulocytes et de macrophages, GM-CSF-R-alpha, CD116)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma4 (1-447) [<i>Homo sapiens</i> VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfure avec la chaîne légère lambda (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226":229-229")-bisdisulfure
mavrilimumab	inmunoglobulina G4-lambda, anti-[CSF2RA (subunidad alfa del receptor del factor estimulante de colonias de granulocitos y macrófagos, GM-CSF-R-alfa, CD116) de <i>Homo sapiens</i>], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma4 (1-447) [<i>Homo sapiens</i> VH (IGHV1-24*01 (93.80%) -(IGHD)-IGHJ3*02) [8.8.13] (1-120) -IGHG4*01 (121-447)], (134-216')-disulfuro con la cadena ligera lambda (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV1-40*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV	SCKVSGYTLT	ELSIHWVRQA	PGKGLEWMGG	50
FDPEENEIVY AQRFGQGRVTM	TEDTSTDTAY	MELSSLRSED	TAVYYCAIVG	100
SFSPPLTLGLW GQRTMVTIVSS	ASTKGPVFP	LAPCSRSTSE	STAALGCLVK	150
DYFPEPVTVS WNSGALTSV	HTFPVAVLQSS	GLYSLSSVVT	VPSSSLGTRK	200
YTCNVDHKPS NTKVDRKVES	KYGPVPCSCP	APEFLGGPSV	PLFPPPKPDT	250
LMISRTPEVT CVVVDVSKQED	PEVQFNWYVD	GVEVHNAKTK	PREEQPNSTY	300
RVVSVLTVLH QDWLNGKEYK	CKVSNKGLPS	SIEKTIKAK	GQPREPQVYV	350
LPFSQEQEMTK NQVSLTCLVK	GFYPSTIAVE	WESNGQPENN	YKTTTPVLDL	400
DGSFFLYSRL TVDKSRWQEG	NVPSCSVMHE	ALHNHYTQKS	LSLSLGK	447

Light chain / Chaîne légère / Cadena ligera

QSVLTQPPSV SGAPGQRVTI	SCTGSGSNIG	APYDVSWYQQ	LPFGTAPKLLI	50
YHNKRPSPGV PDRFSGSKSG	TSASLAITGL	QAEDEADYIC	ATVEAGLSGS	100
VFGGGTKLTV LGQPKAAPSV	TLFPPSSEEL	QANKATLVCL	ISDFYPGAVT	150
VAWKADSSPV KAGVETTPS	KQSNNKYAAS	SYLSLTPEQW	KSHRSYSCQV	200
THEGSTVEKT VAPTECS				217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-L	22'-90'	139'-198'		
	22"'-90"	139"'-198"		
Inter-H-L	134-216'	134"-216"		
Inter-H-H	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297"

moxetumomabum pasudotoxum #
moxetumomab pasudotox

immunoglobulin Fv fragment fused to *Pseudomonas* toxin, anti- [*Homo sapiens* CD22 (sialic acid-binding Ig-like lectin 2, Siglec-2, SIGLEC2, Leu-14, B-lymphocyte cell adhesion molecule, BL-CAM)], *Mus musculus* monoclonal antibody disulfide stabilized Fv fragment with the variable heavy VH domain fused with the truncated form PE38 of *Pseudomonas aeruginosa* exotoxin A (VH-PE38), disulfide linked with the variable kappa domain (V-KAPPA)]; VH-PE38 (1-476) comprising the VH domain (1-123) [methionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fused with a 7-mer linker (124-130) and with the *Pseudomonas aeruginosa* exotoxin A (ETA) PE38 fragment (131-476) [277-638 precursor fragment with del 389-405>N (131-476), containing domain II (131-243) with furin proteolytic cleavage site (152-164), domain Ib (244-267), domain III (268-476)], (45-101')-disulfide with V-KAPPA (1'-108') [methionyl -*Mus musculus* V-KAPPA [(IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

moxétumomab pasudotox

fragment Fv d'immunoglobuline fusionné à la toxine de *Pseudomonas*, anti-[*Homo sapiens* CD22 (Ig-like lectine 2 liant l'acide sialique, Siglec-2, SIGLEC2, Leu-14, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM)], *Mus musculus* fragment Fv d'anticorps monoclonal stabilisé par un pont disulfure avec le domaine VH de la chaîne lourde fusionné à la forme tronquée PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (VH-PE38), lié par un pont disulfure au domaine variable kappa (V-KAPPA)]; VH-PE38 (1-476) comprenant le domaine VH (1-123) [méthionyl -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionné à un 7-mer linker (124-130) et au fragment PE38 de l'exotoxine A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragment précurseur 277-638 avec del 389-405>N (131-476), comprenant domaine II (131-243) dont le site de clivage protéolytique par la furine (152-164), domaine Ib (244-267), domaine III (268-476)], (45-101')- disulfure avec V-KAPPA (1'-108') [méthionyl- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

moxetumomab pasudotox

fragmento Fv de inmunoglobulina fusionado con toxina de *Pseudomonas*, anti-[*Homo sapiens* CD22 (lectina de tipo inmunoglobulina 2 que se une al ácido siálico, Siglec-2, SIGLEC2, Leu-14, molécula de adhesión celular del linfocito B, BL-CAM)], *Mus musculus* fragmento Fv de anticuerpo monoclonal estabilizado por un puente disulfuro con el dominio VH de la cadena pesada fusionado a la forma truncada PE38 de la exotoxina A de *Pseudomonas aeruginosa* (VH-PE38), unida por un puente disulfuro al dominio variable kappa (V-KAPPA)]; VH-PE38 (1-476) que comprende el dominio VH (1-123) [metionil -*Mus musculus* VH [(IGHV5-12-1*01 -(IGHD)-IGHJ3*01) [8.8.16] (2-123)] fusionado a un heptámero de unión(124-130) y al fragmento PE38 de la exotoxina A de *Pseudomonas aeruginosa* (ETA) (131-476) [fragmento precursor 277-638 con del 389-405>N (131-476), comprende el dominio II (131-243) con el sitio de ruptura proteolítica por la furina (152-164), dominio Ib (244-267), dominio III (268-476)], (45-101')- disulfuro con V-KAPPA (1'-108') [metionil- *Mus musculus* V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (2'-108')]

VH-PE38 chain / Chaîne VH-PE38 / Cadena VH-PE38
 MEVQLVESGG GLVKPGGSLK LSCAASGFAP SIYDMSWVRQ TPEKCLEWVA 50
 YISSGGTTY YPDTVKGRFT ISRDNAKNTL YLQMSLSE DTAMYCARH 100
 SGYGHGVL FAYWQGLV TVSAKASGGP EGGSLAALTA HQACHLPLET 150
 FTRHRQPRGW EQLEQCGYVP QRLVALYLAA RLSWNQVDQV IRNALASPGS 200
 GDDLGEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG AANGPADSGD 250
 ALLERNYPTG AEFLGDGGDV SFSTRGTQNW TVERLLQAHR QLEERGVFV 300
 GYHGTFLAQA QSIIVFGGVRV RSQDLDAIWR GFYIAGDPAL AYGYAQDQEP 350
 DARGRIRNGA LLRVYVPRSS LPGFYRTSLT LAAPPAAGEV ERLIGHPLPL 400
 RLDAITGPEE EGGRLTILG WPLAERTVVI PSAIPTDPRN VGGDLDPSSI 450
 PDKEQAISAL PDYASQPGKP PREDLK 476

V-KAPPA chain / Chaîne V-KAPPA / Cadena V-KAPPA
 MDIQMTQTTT SLSASLGDRV TISCRAQDI SNYLNWYQQK PDGTVKLLIY 50
 YTSILHSGVP SRFSGSGSGT DYSLTISNLE QEDFATYFCQ QGNTLPWTFG 100
 CGTKLEIK 108

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 23-97 144-166
 Intra-L 24'-89'
 Inter-H-L 45-101'

narlaprevirum
 narlaprevir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-dimethyl-2-[(1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl)carbamoyl]amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide


narlaprévir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-diméthyl-2-[(1-[(2-méthylpropane-2-sulfonyl)méthyl]cyclohexyl)carbamoyl]amino]butanoyl]-6,6-diméthyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

narlaprevir

(1*R*,2*S*,5*S*)-*N*-[(3*S*)-1-(ciclopropilamino)-1,2-dioxoheptan-3-yl]-3-[(2*S*)-3,3-dimetil-2-[(1-[(2-metilpropane-2-sulfonyl)metil]ciclohexil)carbamoi]amino]butanoil]-6,6-dimetil-3-azabicyclo[3.1.0]hexane-2-carboxamida

C₃₆H₆₁N₅O₇S



omadacyclinum
 omadacycline


(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropyl)amino]methyl]-3,10,12,12*a*-tetrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotetracene-2-carboxamide

omadacycline

(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(diméthylamino)-9-[(2,2-diméthylpropyl)amino]méthyl]-3,10,12,12*a*-tétrahydroxy-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

omadaciclina

(4*S*,4*aS*,5*aR*,12*aS*)-4,7-bis(dimetilamino)-9-[(2,2-dimetilpropil)amino]metil]-3,10,12,12*a*-tetrahidroxi-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahidrotetraceno-2-carboxamida

C₂₉H₄₀N₄O₇**omecantivum mecarbilum**

omecantiv mecarbil


methyl 4-[(2-fluoro-3-[[N-(6-methylpyridin-3-yl)carbamoyl]amino]phenyl)methyl]piperazine-1-carboxylate

omécantiv mécarbíl

4-[(2-fluoro-3-[[N-(6-méthylpyridin-3-yl)carbamoyl]amino]phényl)méthyl]pipérazine-1-carboxylate de méthyle

omecantiv mecarbilo

4-[(2-fluoro-3-[[N-(6-metilpiridin-3-il)carbamoil]amino]fenil)metil]piperazina-1-carboxilato de metilo

C₂₀H₂₄FN₅O₃**plinabulinum**


plinabulin

(3*Z*,6*Z*)-3-benzylidene-6-[[5-(*tert*-butyl)-1*H*-imidazol-4-yl]methylidene]piperazine-2,5-dione

plinabuline

(3*Z*,6*Z*)-3-benzylidène-6-[[5-(*tert*-butyl)-1*H*-imidazol-4-yl]méthylidène]pipérazine-2,5-dione

plinabulina

(3*Z*,6*Z*)-3-bencilideno-6-[[5-(*terc*-butil)-1*H*-imidazol-4-il]metilideno]piperazina-2,5-dionaC₁₉H₂₀N₄O₂**pridopidinum**

pridopidine


4-[3-(methanesulfonyl)phenyl]-1-propylpiperidine

pridopidine

4-[3-(méthanesulfonyl)phényl]-1-propylpipéridine

pridopidina

4-[3-(metanosulfonyl)fenil]-1-propilpiperidina

$C_{15}H_{23}NO_2S$ **raseglurantum**

raseglurant


2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine

raségglurant

2-[2-(3-fluorophényl)éthynyl]-4,6-diméthylpyridin-3-amine

raseglurant

2-[2-(3-fluorofenil)etiniil]-4,6-dimetilpiridin-3-amina

 $C_{15}H_{13}FN_3$ **remimazolamum**

remimazolam


methyl 3-((4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl)propanoate

rémimazolam

3-((4S)-8-bromo-1-méthyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazépin-4-yl)propanoate de méthyle

remimazolam

3-((4S)-8-bromo-1-metil-6-(piridin-2-il)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-il)propanoato de metilo

 $C_{21}H_{19}BrN_4O_2$ **resminostatum**

resminostat

(2E)-3-[1-({4-[(dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyprop-2-enamide

resminostat

(2E)-3-[1-({4-[(diméthylamino)méthyl]phényl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyprop-2-énamide

resminostat

(2E)-3-[1-({4-[(dimetilamino)metil]fenil}sulfonyl)-1H-pirrol-3-il]-N-hidroxirop-2-enamida

sécukinumab immunoglobuline G1-kappa, anti-[*Homo sapiens* interleukine 17A (IL17A, IL-17A)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (236-236":239-239")-bisdisulfure

secukinumab inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-457) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.20] (1-127) -IGHG1*03 (128-457)], (230-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ2*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero bisdisulfuro-(236-236":239-239")

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMNWVRQA PGKGLEWVAA 50
 INQDSEKYY VGSVKGRFTI SRDNAKNSLY LQMNSLRVED TAVYYCVRDY 100
 YDILTDYYIH YWYFDLWGRG TLVTVSSAST KGPSVFFLAP SSKSTSGGTA 150
 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 200
 SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGGPSV 250
 FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
 QPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
 YKTTTPPVLD SDFPFYLYSKL TVDKSRWQQG NVPFSCSVMHE ALHNHYTQKS 450
 LSLSPGK 457

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY 50
 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPCTFG 100
 QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNLF YPREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYKHK KVVACEVTHQ 200
 GLSSPVTKSF NRGEC 215


Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-96 154-210 271-331 377-435
 22"-96" 154"-210" 271"-331" 377"-435"
 Intra-L 23'-89' 135'-195'
 23"'-89"' 135"'-195"
 Inter-H-L 230-215' 230'-215"
 Inter-H-H 236-236" 239-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 307, 307"

selexipagum
selexipag 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide

sélexipag 2-{4-[(5,6-diphénylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(méthanesulfonyl)acétamide

selexipag 2-{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}-N-(metanosulfonyl)acetamida

C₂₆H₃₂N₄O₄S

sotaterceptum #
sotatercept

fusion protein for immune applications (FPIA) comprising ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with immunoglobulin G1 Fc fragment, and binding activin, a member of the TGF beta family;
ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [*Homo sapiens*IGHG1*03 hinge (120-127), CH2, A115>V (128-237), CH3 (238-344)]; (123-123':126-126')-bisdisulfide dimer

sotatercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'ACVR2A (récepteur type 2A de l'activine, récepteur type IIA de l'activine) fusionné au fragment Fc de l'immunoglobuline G1, et liant l'activine, un membre de la famille du TGF bêta;
fragment précurseur 21-135 de ACVR2A (1-115) -linker thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-344) [*Homo sapiens*IGHG1*03 charnière (120-127), CH2, A115>V (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

sotatercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) fusionado al fragmento Fc de la inmunoglobulina G1, y que capta la activina, un miembro de la familia del TGF beta;
fragmento precursor 21-135 de ACVR2A (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [*Homo sapiens*IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro

C₃₄₄₈H₅₂₆₄N₉₂₀O₁₀₅₈S₄₂

Fused chain / chaîne fusionnée / cadena fusionada

```

ILGRSETQEC LFFNANWEKD RTNQTGVPEPC YGDKDKRRHC FATWKNISGS 50
IEIVKQGCWL DDINCYDRTD CVEKKDSPEV YFCCCEGNMC NEKFSYFPPEM 100
EVTQPTSNEV TPKPPTGGGT HTPPCPAPF LLGGPSVFLF PPKPKDTLMI 150
SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 200
SVLTVLHQDW LNGKEYCKV SNKALPVPIE KTISKAKGQP REPQVYTLPP 250
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 300
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 344

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-chain 10-40 30-58 65-84 71-83 85-90 158-218 264-322
              10'-40' 30'-58' 65'-84' 71'-83' 85'-90' 158'-218' 264'-322'
Inter-chains 123-123' 126-126'

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

23, 46, 194, 23', 46', 194'

suvizumabum # suvizumab	immunoglobulin G1-kappa, anti-[human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 third variable loop V3], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG1*01 (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; (227-227":230-230")-bisdisulfide dimer
suvizumab	immunoglobuline G1-kappa, anti-[troisième boucle variable V3 de la glycoprotéine d'enveloppe gp120 du virus type 1 de l'immunodéficience humaine (VIH-1)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG1*01 (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; dimère (227-227":230-230")-bisdisulfure
suvizumab	immunoglobulina G1-kappa, anti-[tercer bucle variable V3 de la glicoproteína de la envoltura gp120 del virus tipo 1 de la inmunodeficiencia humana (VIH-1)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado(<i>Homo sapiens</i> IGHV1-46*01 (77.60%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) - <i>Homo sapiens</i> IGHG1*01 (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (<i>Homo sapiens</i> IGKV4-1*01 (77.20%) -IGKJ1*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; dímero bisdisulfuro-(227-227":230-230")

Heavy chain / Chaîne lourde / Cadena pesada

QQVLVQSGAE VKKPGASVKV SCKASGYTFT NSWIGWFRQA PGQGLEWIGD 50
 IYPGGGYTNY NEIFK GKATM TADTSTNTAY MELSSLRSED TAVYYCSRGI 100
 PGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEPVTVSWN SGALTSVGVHT FPAVLQSSGL YLSLSVVTVP SSSLGTQTYI 200
 CNVNHKPSNT KVDKKEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 TLPSPRDEL TKNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQRPDS LSASVGDRTV MSCKSSQSLN NSGDQKNYLT WYQQKPGQPP 50
 KLLIYWASTG ESGVPRDFSG SSGTDFDFTT ISSLQPEDIA TYQCNDYSY 100
 PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNFPYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSITLTSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 21-96 145-201 262-322 368-426
 21"-96" 145"-201" 262"-322" 368"-426"
 Intra-L 23'-94' 140"-200"
 23"-94" 140"-200"
 Inter-H-L 221-220' 221"-220"
 Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

tafoxiparinum natricum

tafoxiparin sodium

sodium salt of a low molecular mass heparin that is obtained by periodate oxidative depolymerization of heparin from porcine intestinal mucosa followed alkaline β -elimination and reduction of the products; the majority of the components have a 2-deoxy-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopyranosyl structure at the non-reducing end and a (hydroxymethyl)allyl 2-deoxy-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopyranoside structure at the reducing end of their chain; the average molecular mass is approximately 6000 Daltons and 80% of the components ranging between 2000 and 10000 Daltons; the degree of sulfatation is of 2 to 2.5 per disaccharidic unit

tafoxiparine sodique

sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation oxydative, à l'aide de periodate, d'héparine de muqueuse intestinale de porc, suivie d'une β -élimination alcaline puis d'une réduction des produits. La majorité des composants présentent une structure 2-déoxy-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopyranosyle à l'extrémité non réductrice et une structure 2-déoxy-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopyranoside de (hydroxyméthyl)allyle à l'extrémité réductrice de leur chaîne; les masses moléculaires relatives des constituants ont une moyenne voisine de 6000 Daltons et celles de 80% des constituants sont comprises entre 2000 et 10000; le degré de sulfatation est compris entre 2 et 2,5 par unité disaccharide

tafoxiparina sódica

sal sódica de la heparina de baja masa molecular obtenida de mucosa intestinal de cerdo por despolimerización oxidativa mediante un proceso controlado en el que se utiliza periodato, seguido de una β -eliminación alcalina y de una reducción de los productos. La mayoría de los componentes presentan la estructura 2-desoxi-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopiranosilo en el extremo no reductor y la estructura 2-desoxi-6-*O*-sulfo-2-(sulfoamino)- α -D-glucopiranosido de (hidroximetilo)alilo en el extremo reductor de su cadena; la masa molecular relativa media es de aproximadamente 6000 daltons y la masa molecular relativa media de 80 % de los componentes está comprendida entre 2000 y 10000, el grado de sulfatación oscila entre 2 y 2,5 por unidad de disacárido

tenifatecanum

tenifatecan


(4*S*)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-yl (2*R*)-2,5,7,8-tetramethyl-2-[(4*R*,8*R*)-4,8,12-trimethyltridecyl]-3,4-dihydro-2*H*-chromen-6-yl butanedioate

ténifatécan

butanedioate de (4*S*)-4,11-diéthyl-4-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-9-yle et de (2*R*)-2,5,7,8-tétraméthyl-2-[(4*R*,8*R*)-4,8,12-triméthyltridécy]-3,4-dihydro-2*H*-chromén-6-yle

tenifatecán

butanodioato de (4*S*)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-9-ilo y (2*R*)-2,5,7,8-tetrametil-2-[(4*R*,8*R*)-4,8,12-trimetiltridecil]-3,4-dihidro-2*H*-cromen-6-ilo

$C_{55}H_{72}N_2O_9$ **tideglusibum**

tideglusib


4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione

tidégusib

4-benzyl-2-(naphthalén-1-yl)-1,2,4-thiadiazolidine-3,5-dione

tideglusib

4-bencil-2-(naftalen-1-il)-1,2,4-tiadiazolidina-3,5-diona

 $C_{19}H_{14}N_2SO_2$ **tivozanibum**

tivozanib


1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea

tivozanib

1-{2-chloro-4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl}-3-(5-méthyl-1,2-oxazol-3-yl)urée

tivozanib

1-{2-cloro-4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-3-(5-metil-1,2-oxazol-3-il)urea

 $C_{22}H_{19}ClN_4O_5$ 

tonapofyllinum


tonapofylline

3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoic acid

tonapofylline

acide 3-{4-[2,6-dioxo-1,3-dipropyl-2,3,6,7-tétrahydro-1*H*-purin-8-yl]bicyclo[2.2.2]octan-1-yl}propanoïque

tonapofilina

ácido 3-{4-[2,6-dioxo-1,3-dipropil-2,3,6,7-tetrahidro-1*H*-purin-8-il]biciclo[2.2.2]octan-1-il}propanoicoC₂₂H₃₂N₄O₄**topiroxostatam**


topiroxostat

4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat

4-[5-(pyridin-4-yl)-1*H*-1,2,4-triazol-3-yl]pyridine-2-carbonitrile

topiroxostat

4-[5-(piridin-4-il)-1*H*-1,2,4-triazol-3-il]piridina-2-carbonitriloC₁₃H₈N₆**tralokinumabum #**

tralokinumab

immunoglobulin G4-lambda, anti-[*Homo sapiens* IL13 (interleukin 13, IL-13)], *Homo sapiens* monoclonal antibody;
 gamma4 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01 (123-449)], (136-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; (228-228":231-231")-bisdisulfide dimer

tralokinumab

immunoglobuline G4-lambda, anti-[*Homo sapiens* IL13 (interleukine 13, IL-13)], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (228-228":231-231")-bisdisulfure

tralokinumab

inmunoglobulina G4-lambda, anti-[IL13 (interleukina 13, IL-13) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-449) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD)-IGHJ2*01) [8.8.15] (1-122) -IGHG4*01(123-449)], (136-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*03 (93.70%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGLSWVRQA PGQGLEWMGW 50
 ISANNGDTNY GQEFQGRVTM TTDTSSTAY MELRSLRSD TAVYYCARD 100
 SSSWARWFFD LWGRGLTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
 VKDYFPEPVV VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPSSSLGT 200
 KTYTCNVVHK PSNTKVDKRV ESKYGPCCPS CPAPEFLGGP SVFLFPPKPK 250
 DTLMISRTPV VTCVVVDVSO EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
 TYRVVSVLTV LHQDNLNGKE YKCKVSNKGL PSSIEKTIK AKGQPREPQV 350
 YTLPPSQEEM TKNQVSLTCL VKGFPYSDIA VEWESNGQPE NNYKTTTPVL 400
 DSDGSFFLYS RLTVDKSRWQ EGNVFCSSVM HEALHNYTQ KSLSLSLGK 449

Light chain / Chaîne légère / Cadena ligera

SYVLTPPPSV SVAPGKTARI TCGGNIIGSK LVHWYQKPKG QAPVLVIYDD 50
 GDRPSGIPER FSGSNSGNTA TLTISRVEAG DEADYQCQVW DTGSDPVVFG 100
 GGTKLTVLQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
 KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWQKSH RYSYSCQVTHE 200
 GSTVEKTVAP TECS 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 263-323 369-427
 22"-96" 149"-205" 263"-323" 369"-427"

Intra-L 22'-87' 136'-195'
 22"'-87"" 136""-195""

Inter-H-L 136-213' 136"-213"

Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 299, 299"

varlitinibum

varlitinib


N^4 -{3-chloro-4-[(1,3-thiazol-2-yl)methoxy]phenyl}- N^6 -[(4*R*)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib

N^4 -{3-chloro-4-[(1,3-thiazol-2-yl)méthoxy]phényl}- N^6 -[(4*R*)-4-méthyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

varlitinib

N^4 -{3-cloro-4-[(1,3-tiazol-2-il)metoxi]fenil}- N^6 -[(4*R*)-4-metil-4,5-dihidro-1,3-oxazol-2-il]quinazolina-4,6-diamina

C₂₂H₁₉ClN₆O₂S

veliparibum

veliparib


2-[(2*R*)-2-methylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

véliparib

2-[(2*R*)-2-méthylpyrrolidin-2-yl]-1*H*-benzimidazole-4-carboxamide

veliparib

2-[(2*R*)-2-metilpirrolidin-2-il]-1*H*-benzoimidazol-4-carboxamida

C₁₃H₁₆N₄O**verucerfontum**


verucerfont

3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-*N*-[(1*S*)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

vérucefont

3-(4-méthoxy-2-méthylphényl)-2,5-diméthyl-*N*-[(1*S*)-1-(3-méthyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-*a*]pyrimidin-7-amine

verucerfont

2,5-dimetil-3-(2-metilfenil-4-metoksi)-*N*-[(1*S*)-1-(3-metil-1,2,4-oxadiazol-5-il)propil]pirazolo[1,5-*a*]pirimidin-7-aminaC₂₂H₂₆N₆O₂**volasertibum**


volasertib

N-{*trans*-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-[[[(7*R*)-7-ethyl-5-methyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tetrahydropteridin-2-yl]amino]-3-methoxybenzamide

volasertib

N-{*trans*-4-[4-(cyclopropylméthyl)pipérazin-1-yl]cyclohexyl}-4-[[[(7*R*)-7-éthyl-5-méthyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tétrahydroptéridin-2-yl]amino]-3-méthoxybenzamide

volasertib

N-{*trans*-4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}-4-[[[(7*R*)-7-etil-5-metil-6-oxo-8-(propan-2-il)-5,6,7,8-tetrahydropteridin-2-il]amino]-3-metoxibenzamidaC₃₄H₅₀N₈O₃

vonicozumab alfa #

vonicozumab alfa

[618-threonine,709-aspartic acid]von Willebrand factor *Homo sapiens* (1381A>T,1472H>D variant)

vonicozumab alfa

[618-thréonine,709-acide aspartique]facteur de von Willebrand *Homo sapiens* (variant 1381A>T,1472H>D)

vonicozumab alfa

[618-treonina,709-ácido aspático]factor de von Willebrand *Homo sapiens* (variante 1381A>T,1472H>D)C₉₇₁₂H₁₅₃₇₃N₂₇₃₇O₃₀₃₂S₂₁₀

SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG 50
 MVRHENRCVA LERCPCFHQG KEYAPGETVK IGCNTCVCRD RKWNCTDHC 100
 DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG TFRILVGNKG 150
 CSHPSVKCKK RVTLVEGGE IELFDGEVNV KRPMKDETHF EVVESGRYII 200
 LLLGKALSIV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ NNDLTSSNLQ 250
 VEEDPVDFGN SWKVSSQCAD TRKVPDLDSSP ATCHNNIMKQ TMVDSSCRIL 300
 TSDVFDQCNK LVDPEPYLDV CIYDTCSCES IGDCAFCDDT IAAYAHVCAQ 350
 HGKVVVTRTA TLCPQSCCEER NLRENGYECE WRYNSCAPAC QVTCQHPPEL 400
 ACPVQCEVGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG RRFASGKVT 450
 LNPSPDEHGC ICHCDVVNLT CEACQEPGGL VVPTDAPVS PTTLVVEDIS 500
 EPPLHDFYCS RLLDLVFLLD GSSRLSEAEF EVLKAFVVDV MERLRISQKW 550
 VRVAVVEYHD GSHAYIGLKD RKRPSSELRI ASQVKYAGSQ VASTSEVLKY 600
 TLFQIFSKID RPEASRITLL LMASQEPQRM SRNFVRYVQG LKKKKIVIP 650
 VGIGPHANLK QIRLIEKQAP ENKAFVLSV DELEQQRDEI VSYLCLDAPE 700
 APPPTLPPDM AQVTVGPGLL GVSTLGPKNR SMVLDVAFVL EGSCKIGEAD 750
 FNRSKEFMEE VIQRMDVQGD SIHVTVLQYS YMVTVEYPPS EAQSKGDILQ 800
 RVREIRYQGG NRTNTGLALR YLSDHSFLVS QGDREQAPNL VYMTGNPAS 850
 DEIKRLPGDI QVVPVIGVGN ANVQELERIG WPNAPILIQD FETLPREAPD 900
 LVLQRCCSGE GLQIPTLSPA PDCSQPLDVI LLLDGSSEFP ASYFDEMKSF 950
 AKAFISKANI GPRLTQVSVL QYGSITIDV PWNVPEKAH LLSLVDVMQR 1000
 EGGPSQIGDA LGFAVRYLTS EMHGARGPAS KAVVILVTDV SVDSDVDAAD 1050
 AARSNRVTVF PIGIGDRYDA AQLRILAGPA GDSNVVKLQR IEDLPTMVTL 1100
 GNSFLHKLCS GFVRIEMDED GNEKRPDGVW TLPDQCHTVT CQPDGQTLK 1150
 SHRNVNDRGL RPSCPNSQSP VKVEETCGCR WTCPCVCTGS STRHIVTFDG 1200
 QNFKLTGSCS YVLFQNKQED LEVILHNGAC SPGARQCGMK SIEVHKSALS 1250
 VELHSDMEVT VNGRLVSVPY VCGNMEVNVY GAIMHEVRFN HLGHIPTFTF 1300
 QNNEFQLQLS PKTFASKTYG LCGICDENG A NDFMLRDTV TTDWTKLVQE 1350
 WTVQRPQGTQ QPILLEEQLV PDSHHCQVLL LPLFAECHVK LAPATFYAIC 1400
 QQDSCHQEQV CEVIASYAHL CRTNGVCVDW RTPDFCAMSC PPSLVYNHCE 1450
 HGCPRHCDGN VSSCGDHPSE GCFPCPPDKVM LEGSCVPEEA CTQCIGEDGV 1500
 HQQFLEAWVP DHQPCQICTC LSGRKNVCTT QPCPTAKAPT CGLCEVARLR 1550
 QNADQCCPEY ECVCDPVSCD LPPVPHCERG LQPTLNTPE CRPNFTACACR 1600
 KEECKRVSP SCPPHRLPTL RKTQCCDEYE CACNCVNSTV SCPLGYLAST 1650
 ATNDCGCTTT TCLPDKVCVH RSTIYPVQGF WEEGCDVCTC TMEDAVMGL 1700
 RVAQCSQKPC EDSRCRSGFTY VLHEGECGR CLPSACEVVT GSPRGSQSS 1750
 WKSVMGQWAS PENPCLINEC VRVKEEVFIQ QRNVSCPQLE VPCVPSGFOL 1800
 SKTSAACCP S CR CERMEACM LNGTVIGPGK TVMIDVCTTC RCMVQGVVIS 1850
 GFKLECRKTT CNPCPLGYKE ENNTGECGR CLPTACTIQL RGGQIMTLKR 1900
 DETLDQGDCT HFCKVNERGE YFWEKRVTCG PPFDEHKCLA EGGKIMKIFG 1950
 TCCDTCFEEPE CNDITARLQY VKVGSKSEV EVDIHYCQGK CASKAMYSID 2000
 INDVQDQCS C SPTRTEPMQ VALHCTNGSV VYHEVLNAME CKCSPRKCSK 2050

yttrium (⁹⁰Y) clivatuzumab tetraxetanum #
yttrium (⁹⁰Y) clivatuzumab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, yttrium (⁹⁰Y) radiolabelled tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens*IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens*IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; yttrium (⁹⁰Y) radiolabelled tetraxetan (DOTA) conjugate

yttrium (⁹⁰Y) clivatuzumab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan et radiomarqué à l'yttrium (⁹⁰Y); chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxétan (DOTA) et radiomarqué à l'yttrium (⁹⁰Y)

yttrio (⁹⁰Y) clivatuzumab tetraxetán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado al tetraxetano y radiomarcado con yttrio (⁹⁰Y); cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizada (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimero (228-228":231-231")-bisdisulfuro; conjugada al tetraxetano (DOTA) y radiomarcado con yttrio (⁹⁰Y)

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY 50
INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSLRLSDD TAVYYCARGF 100
GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSVGH TFPVAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVPEK SCDKTHTCP CPAPPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LQDQWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

DIQLTQSPSS LSASVGRVT MTCASSSVS SSYLYWYQQK PGKAPKLWIY 50
STSNLASGVP ARFSGSGSGT DFTLTISLQ PEDSASYFCH QWNRYPYTFG 100
GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSLSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 215

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427

22"-96" 146"-202" 263"-323" 369"-427"

Intra-L 23'-89' 135'-195'


23"'-89'" 135"'-195'"

Inter-H-L 222-215' 222"-215'"

Inter-H-H 228-228" 231-231"

Modified residues / Résidus modifiés / Residuos modificados

Substitution ratio of 2 to 5 lysyl (K)
out of the 90 of the antibody molecule
N⁶-(⁹⁰Y-yttrium tetraxetan)-L-lysyl



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

zoleprodololum


zoleprodolol

 (\pm) -1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoléprodolol

 (\pm) -1-(2-[(3-methoxy-1,2,4-oxadiazol-5-yl)methoxy]phenoxy)-3-[(*tert*-butylamino)]propan-2-ol

zoleprodolol

 (\pm) -1-(2-[(3-metoxi-1,2,4-oxadiazol-5-il)metoxi]fenoxi)-3-[(*terc*-butilamino)]propan-2-ol $C_{17}H_{25}N_3O_5$ and enantiomer
et énantiomère
y enantiómero

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Proposed International Non Proprietary Names (Prop. INN): List 50
Dénominations communes internationales proposées (DCI Prop.): Liste 50
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 50
(WHO Drug Information, Vol. 17, No. 4, 2003)


p. 268 **alvocidibum**
 alvocidib
 alvocidib
 alvocidib

*replace the graphic formula and the chemical name by the following ones
 remplacer la formule développée et le nom chimique par les suivants
 sustitúyase la fórmula desarrollada y el nombre químico por los siguientes*

(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-1-benzopyran-4-one

(-)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-1-benzopyran-4-one

(-)-2-(2-chlorofenil)-5,7-dihidroxi-8-[(3S,4R)-3-hidroxi-1-metilpiperidin-4-il]-4H-1-benzopiran-4-ona



Proposed International Non Proprietary Names (Prop. INN): List 63
Dénominations communes internationales proposées (DCI Prop.): Liste 63
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 43 **aganirsenum**
 aganirsén
 aganirsén

*replace the chemical name by the following
 sustitúyase el nombre químico por el siguiente*

all-P-ambo-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-thymidine

todo-P-ambo-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-timidina

p. 46 **bixalomerum**

bixalomer
bixalomère
bixalómero

replace the chemical name by the following
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

cross linked polymer made of *N,N,N',N'*-tetrakis(3-aminopropyl)butane-1,4-diamine *N* substituted by bivalent substituent groups 2-hydroxypropane-1,3-diyl and 1-(hydroxymethyl)ethylene ($x=20, 45 \leq y \leq 50$)

N,N,N',N'-tétrakis(3-aminopropyl)butane-1,4-diamine *N* substituée par les groupes substituants divalents 2-hydroxypropane-1,3-diyle et 1-(hydroxyméthyl)éthane-1,2-diyle pour former un polymère réticulé ($x=20, 45 \leq y \leq 50$)

N,N,N',N'-tétrakis(3-aminopropil)butano-1,4-diamina *N* sustituida por los grupos sustituyentes divalentes 2-hidroxiopropano-1,3-diilo y 1-(hidroximetil)etileno para formar un polímero reticulado ($x=20, 45 \leq y \leq 50$)

p. 63 delete/supprimer/suprimáse
isopropylis turofexoras
isopropyl de turofexorate

insert/insérer/insértese
turofexoras isopropylis
turofexorate d'isopropyle

- # Electronic structure available on Mednet: <http://mednet.who.int/>
- # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.

